BioSpace News Archive

To close out National Organ Transplantation and Donation Awareness Week, the Honourable Jean-Yves Duclos, Minister of Health, announced funding for two new projects through Innovative Solutions Canada that will focus on cutting-edge research in the area of organ and tissue donation in the hopes of improving those statistics.

Rise in number of cancer patients has led to rise in investments from government to establish specialized hospitals, which is expected to drive market revenue growth.

The data has been collected through extensive primary and secondary research and is validated by experts in the industry.

The industry analysis report is considered a valuable source of information about the global Gonorrhea Testing industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases today announced that the company will be presenting preclinical data on its two lead candidates for geographic atrophy (GA) and wet AMD at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting.

Atara Biotherapeutics, Inc. reported the grant of inducement awards to Charlene Banard, its new Executive Vice President, Chief Technical Officer.

Sutro Biopharma, Inc. announced that on April 26, 2022, the Compensation Committee of Sutro’s Board of Directors granted 155,000 of Sutro Biopharma stock options and 18,000 Restricted Stock Units of Sutro common stock to two new employees.

Sarepta Therapeutics, Inc. granted equity awards on April 29, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 44 individuals hired by Sarepta in April 2022.

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, in collaboration with the University of Oxford, today announced final results from its Phase 2b study in patients with Dupuytren’s disease.

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, has filed its 2021 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2021.